Rocket Lab's Neutron Timeline Slips to 2027, Pushing Profitability Targets Further Out

Rocket Lab investors hoping for a near-term catalyst from the company's next-generation launch vehicle will have to wait longer. The space company confirmed that the maiden flight of its Neutron rocket has been rescheduled for 2027, a retreat from the previous target of the fourth quarter of 2026. The disclosure, filed with the U.S. Securities and Exchange Commission on Wednesday via a Form 8-K, points to manufacturing difficulties affecting the upper dome of the first stage's propellant tank.

The market reaction was swift. The stock shed 7.5% during Wednesday's session and closed at EUR 53.10, with Reuters reporting that the announcement had already weighed on the shares in after-hours trading. More recently, the equity has changed hands at EUR 47.05, down 11% on the day.

Profitability Milestones Shift to the Right

Beyond the technical setback, the delay carries meaningful financial consequences. According to earlier guidance from CFO Adam Spice, a successful Neutron test flight was expected to lift adjusted EBITDA into positive territory in the immediately following quarter, with positive free cash flow projected 18 to 24 months after that milestone. Both targets now drift further into the future. For the third quarter of 2026, Rocket Lab most recently guided toward an adjusted EBITDA loss of between USD 17 million and USD 23 million.

TD Cowen analyst Gautam Khanna reiterated a Buy rating and a USD 90 price target, though he now sees a possible launch window no earlier than the second quarter of 2027. Should Neutron fly fewer times than previously assumed next year, Khanna estimates a potential revenue shortfall of roughly USD 50 million for 2027, alongside potentially higher development costs.

A Fortified Balance Sheet Buys Time

The extended test phase is cushioned by substantial liquidity. At the close of the second quarter of 2026, Rocket Lab reported cash and marketable securities of approximately USD 2.4 billion, bolstered by USD 1.08 billion in proceeds from an at-the-market equity program during the same quarter. The core Electron business continued to expand: second-quarter 2026 revenue climbed to USD 234.066 million, while the net loss narrowed to USD 49.258 million.

Strategically, certifying Neutron on schedule remains essential for competing in the multibillion-dollar U.S. defense market. Under the military's NSSL Lane 1 program, which carries a ceiling of USD 17 billion, a successful Neutron flight is the formal prerequisite for individual task orders. Commercial arrangements are also in the pipeline, including a contract with Kepler at a stated launch price of USD 50 million to USD 55 million.

Analysts Split on Valuation

Views on Wall Street remain mixed. On October 8, Barclays initiated coverage with an Overweight rating and an USD 85 price target. Goldman Sachs, by contrast, maintains a neutral stance with a USD 75 target, trimmed from USD 80.

The stock now sits 60% below its 52-week high following the latest declines, with other gauges putting the gap at minus 65%. That discount suggests investors want hard evidence from the first-stage build before granting the shares fresh valuation premiums — and prompt resolution of the manufacturing issues is the key to locking in the revised 2027 launch date.